Late Toxicities and Long‐term Monitoring in Classical Hodgkin Lymphoma and Diffuse Large B‐cell Lymphoma Survivors: A Series of Systematic Reviews of the Fondazione Italiana Linfomi

Abstract

The number of patients living after a cancer diagnosis is increasing, especially after hemolymphopoietic and thyroid cancer (TC). This study aims at evaluating both the risk of a second hemolymphopoietic cancer in TC patients and the risk of TC as a second cancer.Methods: Two population-based cohorts of cancer patients aged up to 84 years were identified from 28 Italian cancer registries in the 1998-2012. The first included TC patients and the second hemolymphopoietic cancers patients with cancers. Standardized incidence ratios (SIR) of SPC were stratified by sex, age, and time since first cancer. SPC diagnosed within 2 months since first are not included in the computation of cancer-specific SIRs.Results: 38,535 TC patients and 154,820 patients with hemolymphopoietic cancers were included. Overall SIR for hemolymphopoietic cancer in TC patients was significantly increased (SIR=1.5 in women and 1.3 in men), as well as for most of the hemolymphopoietic subtypes (SIR=2.

Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review by the Fondazione Italiana Linfomi

“…The scope of the position statements, as well as the clinical questions and PICOs for each question, were discussed and agreed by the FIL 'Long-term Survivor Committee' and presented at the FIL congress in 2019. The study was not registered on Prospero as part of a larger position paper, which was composed by several papers; the position paper as a whole was presented at the International Conference on Malignant Lymphoma/European Hematology Association annual congress in 2021 [19]. We used the PRISMA guidelines to report the results [20].…”